Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the bacterial metabolism of dietary substrates, modification of host molecules (such as bile acids [BAs], trimethylamine-N-oxide, and short-chain fatty acids), or products directly derived from bacteria. Recent studies have provided new insights into the association between MASLD and the risk of developing chronic kidney disease (CKD). Furthermore, alterations in microbiota composition and metabolite profiles, notably altered BAs, have been described in studies investigating the association between MASLD and the risk of CKD. This narrative review discusses alterations of specific classes of metabolites, BAs, fructose, vitamin D, and microbiota composition that may be implicated in the link between MASLD and CKD.
Citations
Citations to this article as recorded by
Radish Green Extract Attenuates Western Diet-Induced Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice Hye-Bin Lee, Yu Ra Lee, Eunjung Lee, Seong Un Jeong, Jae-Hyun Yoon, Miri Park, Yoonsook Kim, Ho-Young Park Journal of Agricultural and Food Chemistry.2026; 74(1): 874. CrossRef
Multi-omics reveal the key role of gut microbiota metabolism in adenine-induced chronic kidney disease Yijing Xin, Hui Ma, Xiang Li, Ruiyang Sun, Luo Fang, Libin Pan Toxicology and Applied Pharmacology.2026; 509: 117754. CrossRef
Research Progress on the Bile Acid Metabolome in Arteriovenous Fistula Stenosis among Maintenance
Hemodialysis Patients 佩 张 Advances in Clinical Medicine.2026; 16(03): 2204. CrossRef
Creatinine clearance rate predicts all-cause and cardiovascular mortality in patients with MASLD: a Shanghai cohort study Yingqi Hou, Yanqiu Huang, Chenghao Zhang, Wen Gu, Yadan Xu, Shuli Li, Jugang Wu, Jibin Liu, Honglin Liu Frontiers in Medicine.2026;[Epub] CrossRef
Plasma proteome profiling identifies XPNPEP3 as a novel biomarker associated with metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus Hua Ji, Yating Lu, Yichang Liu, Yinguang Jia, Jie Liu, Datong Deng, Mingwei Chen Annals of Medicine.2026;[Epub] CrossRef
Loss of immunometabolic adaptability in MASH: gut-derived signals drive macrophage reprogramming and fibrosis Yan Li, Yuyuan Hu, Yuan He, Yuhang Yang, Dingwen Xue, Erkui Xue, Jinghan Jia, Wei Zhang, Jinxi Wang Frontiers in Immunology.2026;[Epub] CrossRef
Ferroptosis in MASLD: From molecular mechanisms to therapeutic opportunities Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D. Byrne, Wei Xie, Qin-Fen Chen, Yuxing Dong, Fudi Wang, Daolin Tang, Ming-Hua Zheng Med.2026; : 101099. CrossRef
Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges Dario Piatto, Delia De Biasio, Francesco Giustino Cesaro, Gianmario Forcina, Vittoria Frattolillo, Antonio Colucci, Fabio Lamberti, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa Journal of Clinical Medicine.2025; 14(11): 3911. CrossRef
Altered mitochondrial function: a clue therapeutic strategies between metabolic dysfunction-associated steatotic liver disease and chronic kidney disease? Jiang Bai, Lijuan Zhang, Letian He, Yun Zhou Frontiers in Nutrition.2025;[Epub] CrossRef
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi Nutrients.2025; 17(13): 2211. CrossRef
Quyu Huazhuo Decoction alleviates non-Alcoholic steatohepatitis via remodeling the gut microbiota and regulating bile acid and short-chain fatty acid metabolism Lu Lu, Chengting Wu, Juhong Jia, Yuanqin Du, Yujiao Peng, Hongna Huang, Jingjing Huang, Yaobin Nong Journal of Chromatography B.2025; 1267: 124784. CrossRef
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano Exploration of Medicine.2025;[Epub] CrossRef
Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications Wenhua Bai, Zheng Zhu Frontiers in Endocrinology.2025;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis are Associated with Advanced Cardiovascular-Kidney-Metabolic Syndrome in Chinese and US Populations Shidi Hu, Dongmei Wang, Qingtao Yu, Zhi Chen, Weiguo Lu, Yuan Meng, Xuetao Peng, Lan Liu, Heng Wan, Jie Shen Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 4699. CrossRef
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucose-lowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM.
Citations
Citations to this article as recorded by
Association between goiter and type 2 diabetes in a Chinese population: a cross-sectional study using CHNS data Jiajia Song, Xiaofang Han, Kemei Liu, Fei Zhai, Dechao Yin, Xiaohuan Zhu, Ting Hu Frontiers in Endocrinology.2026;[Epub] CrossRef
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta, Aikaterini Kountouri, Ioannis S. Papanikolaou, Vaia Lambadiari, Journal of Clinical Medicine.2025; 14(2): 428. CrossRef
Exploring the Mechanism of Action of GLP-1RAs in the Treatment of Non-Alcoholic Fatty Liver Disease Combined with Diabetes Based on Network Pharmacology 高林 齐 Medical Diagnosis.2025; 15(02): 200. CrossRef
Pathogenesis and Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease Roxana Liana Lucaciu, Sorina Cezara Coste, Adriana Corina Hangan, Mihaela Iancu, Olga Hilda Orășan, Angela Cozma, Sidonia Gog Bogdan, Lucia Maria Procopciuc International Journal of Molecular Sciences.2025; 26(12): 5717. CrossRef
High sensitivity C-reactive protein may be a significant predictor of non-alcoholic fatty liver disease in non-obese adults: A four-year retrospective study Changxi Chen, Jiande Gong, Mengting Li, Shiyu Pan, Guitao Xia, Yuemei Xu, Hongliang Li, Qi Lin Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(12): 104224. CrossRef
MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk Alaa M. Mostafa, Ziyan Pan, Ming-Lung Yu, Necati Örmeci, Yasser Fouad, Mohammed Eslam Hepatic Medicine: Evidence and Research.2025; Volume 17: 75. CrossRef
Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis Rutao Lin, Jianghua Zhou, Qinmei Sun, Xin Xin, Yiyang Hu, Minghua Zheng, Qin Feng Alimentary Pharmacology & Therapeutics.2024; 59(7): 802. CrossRef
Current status and future trends of the global burden of MASLD Lei Miao, Giovanni Targher, Christopher D. Byrne, Ying-Ying Cao, Ming-Hua Zheng Trends in Endocrinology & Metabolism.2024; 35(8): 697. CrossRef
Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials Hao Wang, Qianqian Ma, Youpeng Chen, Ling Luo, Junzhao Ye, Bihui Zhong Obesity Reviews.2024;[Epub] CrossRef
Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research E. V. Biryukova Meditsinskiy sovet = Medical Council.2024; (6): 72. CrossRef
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic Current Issues in Molecular Biology.2024; 46(7): 6300. CrossRef
AI‐based digital pathology provides newer insights into lifestyle intervention‐induced fibrosis regression in MASLD: An exploratory study Hai‐Yang Yuan, Xiao‐Fei Tong, Ya‐Yun Ren, Yang‐Yang Li, Xin‐Lei Wang, Li‐Li Chen, Sui‐Dan Chen, Xiao‐Zhi Jin, Xiao‐Dong Wang, Giovanni Targher, Christopher D. Byrne, Lai Wei, Vincent W.‐S Wong, Dean Tai, Arun J. Sanyal, Hong You, Ming‐Hua Zheng Liver International.2024; 44(10): 2572. CrossRef
Mechanism of Action of Dihydroquercetin in the Prevention and Therapy of Experimental Liver Injury Hewei Wei, Ting Zhao, Xinglong Liu, Qiteng Ding, Junran Yang, Xiaoyu Bi, Zhiqiang Cheng, Chuanbo Ding, Wencong Liu Molecules.2024; 29(15): 3537. CrossRef
Protective Effects of Plum on Liver and Gut Injury in Metabolic Dysfunction-Associated Fatty Liver Disease Ji-Su Kim, Sun-Mee Hong, Do-Kyun Kim, Young-Eun Cho Nutrients.2024; 16(21): 3760. CrossRef
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Michael D. Shapiro, Li-Li Chen, Ming-Hua Zheng Cardiology Plus.2024; 9(4): 275. CrossRef
Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection Tzu-I Chen, Fu-Jen Lee, Wan-Lun Hsu, Yong-Chen Chen, Mingchih Chen Cancers.2023; 15(4): 1148. CrossRef
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different? Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2023; 29(2): 377. CrossRef
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome David S. H. Bell, Terri Jerkins Diabetes, Obesity and Metabolism.2023; 25(11): 3093. CrossRef
Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease Iqra J Mazhar, Mohamed Yasir, Saba Sarfraz, Gandhala Shlaghya, Sri Harsha Narayana, Ujala Mushtaq, Basim Shaman Ameen, Chuhao Nie, Daniel Nechi, Sai Sri Penumetcha Cureus.2023;[Epub] CrossRef
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD) Iryna Kostitska, Nadia Protas, Liliia Petrovska Diabetes Obesity Metabolic Syndrome.2023; (5): 8. CrossRef
Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives Lei Miao, Giovanni Targher, Christopher D. Byrne, Luca Valenti, Xiaolong Qi, Ming‐Hua Zheng Portal Hypertension & Cirrhosis.2022; 1(1): 57. CrossRef
The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy Bo Yuan, Jichun Ma, Jing Wang, Jinyong Hao Frontiers in Endocrinology.2022;[Epub] CrossRef
First
Prev
